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Abstract: Multiple sclerosis (MS) is an immune inflammatory disease, where the underlying 
etiological cause remains elusive. Multiple triggering factors have been suggested including 
environmental, genetic and gender components. However underlying infectious triggers to the 
disease are also suspected. There is an increasing abundance of evidence supporting a viral etiology 
to MS, including the efficacy of interferon therapy and over detection of viral antibodies and nucleic 
acids when compared with healthy patients. Several viruses have been proposed as potential 
triggering agents, including Epstein-Barr virus, Human herpesvirus 6, Varicella-zoster virus, 
Cytomegalovirus, John Cunningham virus and Human endogenous retroviruses. These viruses are 
all near ubiquitous and have a high prevalence in adult populations (or in the case of the 
retroviruses are actually part of the genome). They can establish lifelong infections with periods of 
reactivation, which may be linked to the relapsing nature of MS. In this review, the evidence for a 
role for viral infection in MS will be discussed with an emphasis on immune system activation 
related to MS disease pathogenesis.   
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1. Introduction 
Multiple sclerosis (MS) is a severely debilitating progressive inflammatory disease of the central 
nervous system (CNS) [1].The basic pathology is thought to be auto-immune mediated damage to the 
myelin sheaths of central nerves [2]. This is supported by the finding of plaques, areas of the damage, 
particularly within the white matter around the lateral ventricles of the brain and optic nerves [3,4]. 
Demyelination of the white mater in MS is routinely demonstrated by conventional MRI techniques 
[5]; however, lesions in the grey mater are also demonstrated [6]. It appears that the degree of cortical 
demyelization reflects the clinical progression of MS with demyelination of the grey matter associated 
with the progressive form of the disease along with neuronal loss, while myelin destruction is 
detected in relapsing-remitting MS [7,8]. Cortical lesions can also be detected at the early stages and 
they correlate with the disease severity [9].  
The clinical course of the disease varies greatly from relapsing remitting, where patients have 
periods of remission, to progressive forms. There are four clinical forms of MS: primary progressive 
MS (PPMS), secondary progressive MS (SPMS), relapsing remitting MS (RRMS) and progressive 
relapsing (PRMS) all of which are characterized by periods of active disease with evidence of new 
pathology interspersed with inactive periods [10] (Figure 1). RRMS is the most common form of the 
disease, which is characterized by worsening of clinical symptoms followed by periods of partial or 
complete recovery [11]. RRMS often transitions into a secondary progressive course with worsening 
and steady progression of symptoms [12], which is referred to as SPMS. A small group of patients 
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will develop PPMS with steady progression of neurological symptoms without periods of remission 
[13-15]. PRMS is somewhat similar to PPMS, but these patients have periods of recovery characterized 
by concomitant progression of MS symptoms [15]. The remitting phase of the disease, where the 
periods of remission are followed by worsening of symptoms, closely resembles the progression of 
some viral infections, herpes viruses, in particular. Although, permanent tissue destruction and loss 
of function is not common for reactivation of most of herpesviruses, still, neurological complications 
have shown in some chronic herpesviruses infections [16].  
 
Figure 1. Clinical presentation of MS. RRMS- has worsening of clinical symptoms followed by periods 
of recovery; PPMS - has steady progression of clinical symptoms; SPMS – initial relapsing-remitting 
course followed by steady progression of symptoms; PRMS - steadily progression of clinical 
symptoms with occasional relapses. 
Myelin is the multilamellar sheath formed around the neurons and axons by neuroglial cells [17]. 
Myelin formation is complex process requiring expression of several myelin‐specific proteins: myelin 
basic protein (MBP), myelin‐associated glycoprotein and proteolipid protein [18]. Additionally, 
several minor glycoproteins are present in the myelin sheath including myelin oligodendrocyte 
glycoprotein (MOG) (Figure 2). MOG is expressed on the surface of the myelin, covering the neurons 
and axons [19]. While the function of MOG remains largely unknown, it is believed that this protein 
serves as an adhesion molecule or cellular receptor.  
 
Figure 2.  Myelin-associated glycoprotein (MOG) expression on the surface of the myelin, covering the 
axon. The myelin sheets are held together with Myelin basic protein (MBP) , while MOG is located on 
the surface and exposed to the autoreactive leukocytes. 
A number of risk factors including ethnicity, particular HLA loci, gender (it is more common in 
women), latitude (and therefore sunlight and vitamin D levels) and viral infections have been 
identified as risk factors of MS [20]. A variety of immune modulatory treatments are used with none 
fully able to halt or reverse disease progression. Nevertheless, the effectiveness of interferon beta 
(IFNβ) treatment of MS suggests that antiviral immunity plays a role in the etiology of MS, as this 
cytokine has a potent anti-viral activity [21]. A role in MS pathogenesis  has been suggested for many 
viruses including Epstein-Barr virus (EBV), Human herpesvirus 6 (HHV-6), Varicella-zoster virus 
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(VZV), Cytomegalovirus (CMV), John Cunningham virus (JCV) and Human endogenous retroviruses 
(HERVs)[22-26] 
The association between viral infection and MS is a complex. Although belonging to different 
families, these viruses have in common an ability to manipulate host gene expression, potentially 
leading to immune dysregulation, myelin destruction and inflammation. These are all viruses with 
either a DNA phase or DNA viruses, can cross the blood brain barrier (BBB) and can all establish 
lifelong chronic infection [27]. In this review, the role of several viruses in MS pathogenesis will be 
discussed.  
 
2. Herpesviruses 
 There is an established epidemiological link between herpesvirus infection status and the risk of MS . 
Herpesviruses have a near ubiquitous prevalence in adult populations and are usually contracted in 
the early childhood with little overt disease [28]. There are several herpes virus types known to be 
human pathogens: alpha, beta and gamma [29]. Members of each group, alpha (varicella zoster virus, 
VZV), beta (cytomegalovirus CMV and human herpesvirus 6 HHV-6) and gamma (Epstein Barr virus 
EBV) are all suspected of having potential role in MS. Herpesviruses can establish two replication 
cycles: latency and reactivation. Herpesviruses have multiple targets including neuronal (alpha-
herpesviruses) and non-neuronal (beta and gamma herpesviruses), macrophages and B cells [30,31]. 
Herpesviruses targeting neurons directly or indirectly, via immune response, could contribute to the 
tissue damage found in MS. 
Herpes viruses share many features in their structure including the capsid and tegument 
proteins as well as the envelope (Figure 4). Typically, virus genome is covered by the nucleocapsid 
[32], which is surrounded by the tegument protein [33] [34]. The envelope containing glycoprotein 
spikes wraps the virus outside [35]. The envelop glycoproteins bind to the cell receptors and assist 
with penetration of the target cell [36]. Virus DNA replication, transcription and encapsidation take 
place in the nucleus of infected cells [37,38]. In immunocompetent hosts infection is usually 
asymptomatic, followed by lifelong latency and reactivation [36] [39]. Virus can reactivate, resulting 
in the initiation of a replication cycle and cytopathic effect in infected cell [40]. 
 
Figure 4. Structure of Herpesviruses. The viral DNA is packed inside the capsid, which is wrapped by 
the tegument. The envelope, the outer layer of the virion, is composed by the phospholipids bilayer 
embedded with glycoproteins. 
2.1 Alphaherpesviruses (VZV, HSV-1 and 2)  
VZV reactivation is a recognized complication of the immunosuppressive therapies used in MS 
treatment, in particular Fingolomid (a sphingosine-1-phosphate receptor modulator that acts by 
sequestering lymphocytes in lymph nodes). [41]A history of VZV and an increased antibody response 
to it is more common in MS patients than the general population[41,42]. VZV is also frequently 
detected during active disease phases of MS[43]. It is not clear however whether this detection has 
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any connection to a role in pathogenesis in MS or is an incidental escape of VZV from immune control 
due to MS treatment or disease[44].  
Similarly for HSV-1 and 2 viral encephalitis as complication of the various immunosuppressive 
drugs used in MS therapy is seen [45-47] and there has been some suggestion of increased antibody 
prevalence of HSV-1 and or 2 in MS patients (though potentially only in some cohorts of patients 
[48,49] and this is not repeatable across different cohorts of patients [50]. HSV-1 in rats and mice can 
induce demyelinating encephalitis but it is not clear that this cross species transmission event 
pathology is relevant in humans [51,52].  
2.2 Beta-herpesviruses. CMV. 
The association of CMV and MS pathogenesis remains inconclusive. In two studies higher loads 
of CMV DNA were demonstrated in an Iranian cohort of MS patients when compared to controls 
[53,54]. Corroborating these data were findings that  opportunistic reactivation of CMV infection can 
also occur in MS patients with this  reactivation potentially exacerbating existing MS [55,56]. In 
contrast, multiple other studies have demonstrated a negative correlation between CMV 
seropositivity and MS diagnosis [25,57-60] [61]. A large meta-analysis including 1341 MS and 2042 
controls however failed to conclusively define the relationship between CMV infection and the 
disease [62] These differences may potentially be explained by an effect similar to that described for 
Epstein Barr virus whereby the small number of people who have never been infected with CMV 
have a decreased risk of MS in contrast with reactivation of latent CMV in the active disease phase of 
MS potentially exacerbating existing damage   
 
 Evidence from the two murine models of MS is also conflicting with Pirko et al 2012 , a 
protective effect of the murine version of CMV, MCMV infection in the Theiler’s murine encephalitis 
virus (TMEV) model MS [63]. Wheres Vanheusden et al demonstrated expansion of CD4+CD28null T 
cells in MCMV infection in mice with these cells associated with  
 
, aggravation of  the inflammation, demyelination and worsening symptoms of experimental 
autoimmune encephalomyletis (EAE), a mouse model of MS induced by the injection of myelin 
antigens with adjuvantEAE  [64]. These authors identified circulating CD4+CD28null T cells as the 
leading pathogenic lymphocytes in mice, as their counts correlated with demyelination and disease 
severity. These T cells lack to CD28 co-stimulation factor necessary for activation of T cells and are 
typically expanded in chronic inflammation [65].. The EAE model in mice is not however a perfect 
mirror of MS disease in humans Although a strong correlation between CD4+CD28null T lymphocytes 
and EAE progression has been demonstrated in mice, these cells were expanded only in a small 
group of MS patients and demonstrated  limited autoreactivity [66].Alternative work in the non-
human primate model (the marmoset) with a closer pathology to the human disease has also 
highlighted that the T-cell driven responses in the murine models may not be as important in 
primates and humans [23].   
2.2 Beta-herpesviruses HHV6.  
There are a number of studies linking HHV6 with MS pathogenesis [67]. Strong evidence of the 
role of HHV6 in MS pathogenesis includes an increased prevalence of viral DNA and proteins within 
MS plaques and CSF as compared to healthy patients indicating HHV6 neurotropism [68,69]. Also, 
expression of viral RNA and proteins in periventricular lesions, which are commonly found in MS, 
supports the involvement of HHV6 in MS pathogenesis [70,71]. These findings have been countered 
by other studies failing to report HHV6 detection in MS [72]. However, a recent systematic review 
and Meta-analysis supports an association between HHV-6 antibody and DNA positivity and MS 
[73]. There is also some suggestion of HHV-6 proteins having cross reactivity with myelin basic 
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protein, an essential component of the myelin sheath, which could contribute to CD8+ T cell mediated 
oligodendrocyte death [72].  
 
2.3Gamma Herpesviruses EBV.  
Gamma-herpesvirus EBV association with MS is complex. It appears that EBV seronegative 
status correlates with a decreased risk of MS [74]. Accordingly, patients with infectious 
mononucleosis (IM), have an increased risk of MS as compared to those who are seropositive but with 
no history of IM [75]. Whether the presence of EBV DNA is more likely in MS than “healthy” patients 
is more controversial and remains unproven [75,76] [77]. Also virus detection in the periphery, may 
not correlate with its presence in the CNS [76]. Therefore, some authors hypothesize that EBV 
invasion of the CNS before adaptive immune responses have developed is a crucial factor in MS 
pathogenesis [78]. Multiple mechanisms of EBV MS pathogenesis are currently proposed including 
cross reactivity between virus and myelin epitopes [79], auto-immune responses against alpha-β-
crystallin (a stress protein expressed in lymphoid cells and oligodendrocytes)[80], antibody-
dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity [81]. Despite its’ well-
established role as one of the triggers of the disease, shedding or detection of EBV in either the blood 
or CNS does not appear to be related to relapses or progression of MS [82,83].  
Intriguingly there is also an increasing body of evidence pointing at the role of Epstein-Barr 
Nuclear antigen 2 (EBNA2) in the pathogenesis of MS. EBNA2 can upregulate host gene expression 
and recruit transcription activation factors [84-87]. Interestingly EBNA2 binding in the host cells 
occurs within the known genetic loci associated with MS susceptibility [88]. In this respect, two 
binding sites appear to be most interesting: Recombination signal binding protein for 
immunoglobulin kappa J region (RBPJ) and the vitamin D receptor (VDR). It has been shown that 
EBNA2 can convert resting B cells into immortal cells by engaging the transcription factor RBPJ [89]. 
These immortal B cells could maintain pathogenic autoreactive leukocytes in MS circulatory and 
brain tissue. The EBNA2 overlap with VDR [88] is also of importance as vitamin D deficiency as a 
predisposing factor in MS is well established [90]. Many of the same sites are also implicated in 
systemic lupus erythematosus (SLE), another disease with strong epidemiological links to EBV 
infection [88,91]. These associations are particularly marked in B cells and it would seem that there is 
a competitive interaction for transcription binding sites between EBNA2, promoting B cell 
proliferation, and Vitamin D which down regulates B cell function.  
Further more complicated evidence for a direct role of EBV in MS pathology is provided by the 
marmoset model of MS, which closely mimics the human immune response to EBV [92]. In this 
model, the role of Calithricine herpesvirus 3 (CalHV3) in pathogenesis of MS-like disease was 
explained by direct infection of B cells [93]. Therefore, it appears that the therapeutic efficacy of 
marmoset treatment with anti CD20 monoclonal antibodies (anti B cell antibodies) was associated 
with the depletion of CalHV3 infected B cells [94]. An important aspect of this is the antigen 
presenting capacity of CalHV3 infected B cells is affected resulting in the presentation of citrulinated 
epitopes of MOG, which is resistant to degradation [95]. It was suggested that these epitopes can 
stimulate autoreactive cytotoxic T cells, which can escape thymic deletion.  
The evidence for EBV involvement in MS pathogenesis has been compelling enough for at least 
one trial of EBV specific autologous T cell therapy with in-vitro expanded T cells stimulated to target 
EBV nuclear antigen 1 (EBNA1), latent membrane proteins 1 and 2A (LMP1, LMP2A) and reinfused 
in the donor patient. Seven of the 10 patients treated showed clinical and neurological improvement, 
though it is important to note that this was primarily a safety trial with no control arm[96] 
  
3. Non-herpes viruses associated with MS.  
3.1 JCV  
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JCV (human polyomavirus 2 or John Cunningham Virus) is another near ubiquitous DNA viral 
infection acquired in childhood [97]. JCV is a non-enveloped double-stranded DNA virus which 
associates with cellular histones to form minichromosomes in infected cells [98,99] (Figure 5). It is 
believed that JCV infection occurs during childhood and remains dormant in the stage of latency in 
most individuals [100]. This explains the fact that up to 90% of adults are seropositive for the virus, 
with about 20% shedding it in urine [101,102]. JCV infection does not cause overt disease in 
individuals with functional immune systems [103]. However, in immunocompromised individuals, 
the virus can trigger progressive multifocal encephalopathy (PML), characterized by lytic JCV 
infection of oligodendrocytes and astrocytes in the CNS [104]. It appears that the virus has to undergo 
several mutations to enable it to cross the BBB and replicate in the CNS [105,106].  
 
Figure 5. Structure of JCV. The viral DNA is packed around the Histones in a chromatin-like complex. 
Covered by viral structural proteins VP1, forming the capsid with VP2 and VP3 proteins incorporated. 
Although JCV targets oligodendrocytes and demyelinization, it is not thought to have any role in  
triggering MS pathogenesis. An increased risk of development of PML in MS patients treated with 
natalizumab (a monoclonal antibody targeting alpha integrin and therefore inhibiting all white blood 
cell migration) is a known risk factor of this treatment regime [107]. Currently, the use of this drug is 
therefore limited to only highly active RRMS and patients with tolerance to first-line treatments such 
as IFN β [108]. Why this syndrome should be prevalent with natalizumab and not with other MS 
treatments is not clear; however, it is thought to be related to the induction of increased B cell 
numbers alongside reduced immune surveillance of the CNS [109]. Withdrawal of treatment can 
exacerbate the condition as the influx of suddenly reconstituted immune cells can worsen the 
inflammation caused by JCV, which is often fatal [110]. Hence despite its effectiveness in RRMS, risk 
assessment and monitoring of patients based on JCV seropositivity and antibody titer is necessary in 
treatment decisions with this drug in MS [24]. 
 
3.2 HERVs   
 
HERVs are replication defective retroviral proviruses integrated into the human genome and 
comprising up to 8% of it [111]. Over the millennia, HERV proviral sequences have been integrated 
into the human genome regulatory machinery by functioning as promoters, repressors, poly(A) 
signals, enhancers and alternative splicing sites for many non-viral genes [112,113]. Along with 
beneficial effects, inappropriate expression of HERVs has been shown to cause inflammation, 
aberrant immune reaction and dysregulated gene expression [114-116]. HERVs can be grouped into 
three main classes: class I Gammaretrovirus- and Epsilonretrovirus-like HERVs; class II 
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Betaretrovirus-like HERVs; and class III HERV-L [117]. Expression of Gammaretrovirus HERV family 
members, HERVs-H and W has been shown to be associated with MS diagnosis [118,119] . Although 
not capable of completing a full replication cycle, transcription and translation of individual HERV 
proteins, particularly the HERV-W Env protein syncytin in the human placenta, does occur and has 
been demonstrated in the CNS in MS cases and in some healthy individuals [120-122]. There are 
substantial variations in the proportion of MS patients that test positive for HERV-W viral RNA in the 
serum, which can vary between 50 to 100% and in the viral load detected [123-125]  with our systemic 
Meta-analysis confirming the association between MS and HERV-W expression [22].. The wide 
variation in HERV detection is potentially  explained by population differences in HERV expression 
as well as the differing detection methods used in each study. It appears that the detection of HERV-
W products in the blood of MS patients is associated with a poor prognosis and could serve as a 
predictive marker for conversion of optic neuritis into MS [126,127]. HERV load also correlates 
positively with Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS) 
ratings [128]. The higher HERV-Wexpression in female as compared to male patients, corresponds to 
the gender differences within MS [127]. Further evidence of HERV association with MS pathogenesis 
isprovided bythe detection of HERV-W particles in CSF, changing with the disease progression: 
increasing in relapse and decreasing during remission [129]. HERV antigens can be immunogenic and 
higher antibody reactivity against HERV-W and HERV-H Env epitopes was demonstrated in MS 
patients during relapse [130]. These data suggest that HERV antigens could trigger auto-immune 
responses, leading to systemic activation of T cell-mediated neuropathology and brain tissue damage 
as shown in a SCID mouse model [131]. 
  There is an increasing body of data demonstrating that HERV-W protein expression leads to immune activation 
and inflammation. HERV-W proteins display cross reactivity with MOG and have been demonstrated to bind 
with the HLA DR2 locus implicated in genetic susceptibility to MS [132,133] [134] [135-137]. HERV-W env 
proteins bind to CD14 and TLR4 triggering pro-inflammatory cytokines IL-1β, IL-6, or TNF-α [138-140]. The 
HERV-W Env derived protein syncytin is expressed, specifically in monocytes, T and B lymphocytes and NK 
cells displaying an activated phenotype with expression increasing when these cells were stimulated with LPS. In 
addition binding of syncytin activated monocytes, increased the proportion of the type of non-classical monocyte 
(CD14lowCD16+) associated with MS [141]. Both HERV-W and HERV-H are overexpressed in these non-classical 
monocytes in MS patients [142,143]. Intriguingly the use of HERV driven enhancers (the LTR regions in HERVs 
can turn on nearby genes) is increased in T cells from MS patients specifically activating the immune genes 
CCL20 and IL1R2[144]. While there is argument over whether peripheral immune responses in PBMC can 
induce CNS disease it is also clear that a leaky blood brain barrier in MS can allow the migration of blood borne 
monocytes to the CNS triggering inflammation and myelin damage [145].  
HERV-W or syncytin (there is some argument over whether HERV-W env proteins, can be 
reliably distinguished from each other[146]) have also been shown to inhibit oligodendrocyte 
precursor cell formation and remyelination, an effect that can be blocked by the anti-HERV 
monoclonal antibody GNbAC1 [147] This antibody despite a disappointing lack of effect on clinical 
disease scores in treatment trials with patients did more promisingly demonstrate a reduction in new 
lesions as measured by MRI in treated patients compared with placebo [148]. Recent work has in 
addition demonstrated that HERV-W is present in microglia (brain resident myeloid cells) associated 
with axons in MS patients and that expression of HERV-W in myeloid cells induces a degenerative 
phenotype resulting in damage to myelinated axons [149]  
 
 
 
An interesting cooperation between EBV and HERVs has also been demonstrated in MS patients. 
Irizar et al have shown that EBV reactivates in B cells of female RRMS patients during relapse [150]. It 
appears that EBV-encoded glycoprotein 350 expression stimulates the expression of  the syncytin-1, 
HERV-W coded protein in B cells as well as in astrocytes and monocytes [150]. We have also shown a 
similar effect with EBV infection of B cells triggering increased expression of HERV-W RNA and 
protein [151]. This effect is also seen in young adults with infectious mononucleosis (EBV induced 
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disease) [152] It could be suggested that EBV infection or reactivation could serve as a trigger for 
HERV reactivation, which acting as antigens, could induce an auto-immune response targeting neural 
tissue.  
A similar effect has been recently reported with HHV-6 infection of PBMC and 
astroglyoblastoma cell lines where viral infection or activation of its receptor CD46 triggers HERV-W 
expression and TLR4 activation[153] Similarly HSV-1 infection in neuroepithelioma cell lines with 
HSV-1 also activated HERV-W transcription and protein expression in neuronal and brain endothelial 
cells in culture [154] [155], the activation potentially mediated by HSV-1 intermediate early protein 
(IE1) binding to the HERV-W LTR [156]. Interestingly there is also work showing that the addition of 
both herpesviral and HERV-H antigens to PBMC triggered enhanced cellular immune responses [157] 
4. Antiviral effects of MS treatment   
 The treatments available for MS are all variants of immunomodulatory therapies, most of 
which produce their primary effect via induction of lymphopaenia or a shift to a more TH2 driven 
phenotype [158]. Many of them are also used in cancer therapy and common side effects include an 
increased incidence of opportunistic infections or reactivation of latent infections. Interestingly the 
first drug successfully used in MS is IFNβ, which is also one of the principal antiviral cytokines 
produced by virus infected fibroblasts [159]. It may seem a counterintuitive use of an antiviral 
cytokine to treat an inflammatory disorder but the feedback loops induced by IFNβ inhibit many T 
cell functions [158] 
The more recent MS treatments include humanized monoclonal antibodies against lymphocyte 
surface antigens [160].These include Natalizumab which targets VLA4 (very late antigen 4) which is 
expressed on various leukocytes [161,162]. This is thought to  inhibit the interaction between VLA-4 
and vascular cell adhesion molecule-1 (VCAM-1) which facilitates leukocyte migration across the BBB 
[163-165]. The success of the Natalizumab as MS therapeutic has however hindered by PML 
developing in some patients [166,167]. Another humanized antibody MS therapeutic is Alemtuzumab 
which targets CD52 expressing lymphocytes, monocytes and dendritic cells [168]. It appears that the 
mechanism of Alemtuzumab action is associated with depletion of circulating T and B lymphocytes 
via antibody-dependent and complement-dependent cytolysis [168,169]. Post Alemtuzumab hyper-
rebounding of the B cell population can, however, result in a variety of other autoimmune diseases, a 
common side effect of this treatment [170]. The most recently introduced drug of this class 
Ocrelizumab, and its predecessor Rituxizimab, targets the B cell surface protein CD20, resulting in 
selective depletion of this lymphocyte population [171].  In the context of this review all of these 
therapies, which have been quite successful in MS therapy target immune cells in which EBV or 
HERV expression has been demonstrated and part of the effect of these monoclonal antibody 
therapies may be in reducing the EBV and HERV-W autoreactive cells and antigen load.   
6. Conclusions 
There is increasingly solid evidence for a pathogenic role in the triggering of MS auto-immune 
responses by a failure to control chronic viral infections. Evidence for the herpesviruses EBV and 
CMV points towards patients who have never been infected with these viruses having a decreased 
risk of disease, whereas virus activation and the immune responses associated with this are linked to 
MS pathology. Similarly EBV infection appears to trigger expression of the HERVs that have been 
associated with MS pathogenesis and for both HERVs and Herpesviruses significant cross reactivity 
between viral protein epitopes and the MOG (myelin oligodendrocyte protein) and myelin basic 
proteins that are major targets in MS autoimmunity are evident. Directly opposing effects of vitamin 
D (protective) and EBV EBNA2 (associated with disease) at a molecular level are also apparent. 
Significantly a number of the most commonly used and effective MS treatments also directly induce 
antiviral responses or remove the cells that these herpesviruses (and subsequently retroviruses) 
replicate and are expressed in adding further evidence to a role for these viral infections in MS 
pathogenesis.  
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